Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016

Date: December 21, 2016
Pages: 1093
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until September 1, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M95396F7824EN
Leaflet:

Download PDF Leaflet

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) – Pipeline Review, H2 2016, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 61, 60, 2, 114, 22 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 8, 18 and 6 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Multiple Myeloma (Kahler Disease) Overview
Therapeutics Development
Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies
Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes
Multiple Myeloma (Kahler Disease) - Pipeline Products Glance
Multiple Myeloma (Kahler Disease) - Products under Development by Companies
Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes
Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
Drug Profiles
Multiple Myeloma (Kahler Disease) - Dormant Projects 1022
Multiple Myeloma (Kahler Disease) - Discontinued Products 1048
Multiple Myeloma (Kahler Disease) - Product Development Milestones 1053
Appendix 1060

LIST OF TABLES

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2016
Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Development by Companies, H2 2016 (Contd..11)
Number of Products under Development by Companies, H2 2016 (Contd..12)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Development by Companies, H2 2016 (Contd..17)
Products under Development by Companies, H2 2016 (Contd..18)
Products under Development by Companies, H2 2016 (Contd..19)
Products under Development by Companies, H2 2016 (Contd..20)
Products under Development by Companies, H2 2016 (Contd..21)
Products under Development by Companies, H2 2016 (Contd..22)
Products under Development by Companies, H2 2016 (Contd..23)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by AB Science SA, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Ablynx NV, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by ADC Therapeutics Sarl, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Alissa Pharma, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corp, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Arcarios BV, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Arvinas Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences LLC, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Company, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Biosciences Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Constellation Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Company, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Five Prime Therapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science srl, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by GlyTR Therapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by GP Pharm SA, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma GmbH, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Hutchison MediPharma Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology LLC, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by ImmunGene Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corp, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Jasco Pharmaceuticals LLC, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Juno Therapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corp, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Kancera AB, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Karus Therapeutics Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Kesios Therapeutics Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Kite Pharma Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by LG Life Science LTD, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by MediGene AG, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by MedImmune LLC, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Medivation Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Mesoblast Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax LLC, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Nordic Nanovector ASA, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by OncoPep Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by OXIS International Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Peptinov SAS, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar SA, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Phylogica Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Polyphor Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Progenra Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Quimatryx SL, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals SA, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Sellas Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Selvita SA, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Theravectys SA, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Tragara Pharmaceuticals Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Verastem Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Vivolux AB, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H2 2016
Multiple Myeloma (Kahler Disease) - Pipeline by XTL Biopharmaceuticals Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2016 1054
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..1), H2 2016 1055
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..2), H2 2016 1056
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..3), H2 2016 1057
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..4), H2 2016 1058
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..5), H2 2016 1059
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..6), H2 2016 1060
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..7), H2 2016 1061
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..8), H2 2016 1062
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..9), H2 2016 1063
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..10), H2 2016 1064
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..11), H2 2016 1065
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..12), H2 2016 1066
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..13), H2 2016 1067
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..14), H2 2016 1068
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..15), H2 2016 1069
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..16), H2 2016 1070
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..17), H2 2016 1071
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..18), H2 2016 1072
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..19), H2 2016 1073
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..20), H2 2016 1074
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..21), H2 2016 1075
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..22), H2 2016 1076
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..23), H2 2016 1077
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..24), H2 2016 1078
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..25), H2 2016 1079
Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2016 1080
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..1), H2 2016 1081
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..2), H2 2016 1082
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..3), H2 2016 1083
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..4), H2 2016 1084

LIST OF FIGURES

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2016
Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Charcot-Marie-Tooth Disease - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 56 pages
Meniere Disease - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 43 pages

Ask Your Question

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: